{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.8","upperLimit":"36.9","value":"24.6"},{"groupId":"OG001","lowerLimit":"17.3","upperLimit":"64.3","value":"38.9"},{"groupId":"OG002","lowerLimit":"10.5","upperLimit":"35.0","value":"20.8"},{"groupId":"OG003","lowerLimit":"6.3","upperLimit":"28.9","value":"15.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"46"}],"units":"Participants"}],"description":"Confirmed MCyR is defined as 2 assessments of CCyR or PCyR at least 28 days apart.","dispersionType":"95% Confidence Interval","groups":[{"description":"AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG000","title":"Cohort C: AP-CML R-I"},{"description":"AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG001","title":"Cohort D: AP-CML With T315I Mutation"},{"description":"BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG002","title":"Cohort E: BP-CML/Ph+ ALL R-I"},{"description":"BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).","id":"OG003","title":"Cohort F: BP-CML or Ph+ ALL With T315I Mutation"}],"paramType":"NUMBER","populationDescription":"Treated population included all participants assigned to Cohorts A to F who received at least 1 dose of ponatinib. The data for this outcome measure is applicable for Cohorts C to F only.","reportingStatus":"POSTED","timeFrame":"Every 2 cycles up to 26 cycles, followed by every 3 cycles from cycles 27 through 39, and then every subsequent sixth cycle (Up to approximately 48 months after first dose)","title":"Percentage of AP-CML or BP-CML/Ph+ ALL Participants With Confirmed MCyR","type":"SECONDARY","unitOfMeasure":"percentage of participants"}